Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma

Cancer Science

Volumn 105, Issue 7, 2014, Pages 840-846

  Ogura, Michinori ^a   Tobinai, Kensei ^b   Hatake, Kiyohiko ^c   Ishizawa, Kenichi ^d   Uike, Naokuni ^e   Uchida, Toshiki ^a   Suzuki, Tatsuya ^a   Aoki, Tomohiro ^a   Watanabe, Takashi ^b   Maruyama, Dai ^b   Yokoyama, Masahiro ^c   Takubo, Takatoshi ^f   Kagehara, Hideaki ^f   Matsushima, Takafumi ^f  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f Takeda Bio Development Center Limited   (Japan)

Author keywords

Anaplastic large cell lymphoma; Brentuximab vedotin; Clinical trial; Hodgkin's lymphoma; Japanese patients

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAC10 VCMMAE; CAC10-VCMMAE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASEPTIC MENINGITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RECURRENCE; CELLULITIS; CLINICAL ARTICLE; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HODGKIN DISEASE; HUMAN; HYPOPHOSPHATEMIA; JAPANESE (PEOPLE); LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RASH; RHINOPHARYNGITIS; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ASIAN; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; JAPANESE PATIENTS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ANAPLASTIC LARGE CELL LYMPHOMA; BRENTUXIMAB VEDOTIN; CLINICAL TRIAL; HODGKIN'S LYMPHOMA; JAPANESE PATIENTS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG ADMINISTRATION SCHEDULE; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; TREATMENT OUTCOME;

EID: 84904255041     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12435     Document Type: Article

References (19)

1. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68: 421-7.
2. Falini B, Pileri S, Pizzolo G et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1-14.
3. Doronina SO, Toki BE, Torgov MY et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21: 778-84.
4. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-21.
5. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183-9.
6. Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190-6.
7. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
8. Fanale MA, Forero-Torres A, Rosenblatt JD et al. Phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012; 18: 248-55.
9. Japanese Ministry of Health, Labour, and Welfare. Revision of guidelines for clinical evaluation methods of anti-cancer drugs in Japan. Issued on November 1, 2005. (Japanese)
10. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-95.
11. Sureda A, Constans M, Iriondo A et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16: 625-33.
12. Majhail NS, Weisdorf DJ, Defor TE et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 1065-72.
13. Savage KJ, Harris NL, Vose JM et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496-504.
14. Moskowitz CH, Nimer SD, Glassman JR et al. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant 1999; 23: 561-7.
15. Shipp MA, Abeloff MD, Antman KH et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423-9.
16. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24: 1633-42.
17. Bartlett NL, Niedzwiecki D, Johnson JL et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18: 1071-9.
18. Fehniger TA, Larson S, Trinkaus K et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118: 5119-25.
19. O'Connor OA, Pro B, Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 1182-9.